Phase I Study of the Anti-PD1 Immune Checkpoint Inhibitor Pembrolizumab And Platinum in Combination With Radical radiotherApY in Cervix cAncer.
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Cervical cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PAPAYA
- 21 Feb 2018 Status changed from not yet recruiting to recruiting.
- 10 May 2017 New trial record